» Articles » PMID: 33419237

Growth Differentiation Factor 15: A Biomarker with High Clinical Potential in the Evaluation of Kidney Transplant Candidates

Abstract

Kidney transplantation implies a significant improvement in patient survival. Nevertheless, early mortality after transplant remains high. Growth differentiation factor 15 (GDF-15) is a novel biomarker under study as a mortality predictor in multiple scenarios. The aim of this study is to assess the utility of GDF-15 to predict survival in kidney transplant candidates. For this purpose, 395 kidney transplant recipients with pretransplant stored serum samples were included. The median GDF-15 was 5331.3 (50.49-16242.3) pg/mL. After a mean of 90.6 ± 41.5 months of follow-up, 82 (20.8%) patients died. Patients with higher GDF-15 levels (high risk tertile) had a doubled risk of mortality after adjustment by clinical characteristics ( = 0.009). After adjustment by EPTS (Estimated Post Transplant Survival score) the association remained significant for medium hazards ratios (HR) 3.24 95%CI (1.2-8.8), = 0.021 and high risk tertiles HR 4.3 95%CI (1.65-11.54), = 0.003. GDF-15 improved the prognostic accuracy of EPTS at 1-year (ΔAUC = 0.09, = 0.039) and 3-year mortality (ΔAUC = 0.11, = 0.036). Our study suggests an independent association between higher GDF-15 levels and mortality after kidney transplant, adding accuracy to the EPTS score, an established risk prediction model currently used in kidney transplant candidates.

Citing Articles

Role and Mechanism of Growth Differentiation Factor 15 in Chronic Kidney Disease.

Tang Y, Liu T, Sun S, Peng Y, Huang X, Wang S J Inflamm Res. 2024; 17:2861-2871.

PMID: 38741613 PMC: 11090192. DOI: 10.2147/JIR.S451398.


The Clinical Value of GDF15 and Its Prospective Mechanism in Sepsis.

Li H, Tang D, Chen J, Hu Y, Cai X, Zhang P Front Immunol. 2021; 12:710977.

PMID: 34566964 PMC: 8456026. DOI: 10.3389/fimmu.2021.710977.


The Impact of the Nephrotoxin Ochratoxin A on Human Renal Cells Studied by a Novel Co-Culture Model Is Influenced by the Presence of Fibroblasts.

Schwerdt G, Kopf M, Gekle M Toxins (Basel). 2021; 13(3).

PMID: 33803529 PMC: 8003035. DOI: 10.3390/toxins13030219.

References
1.
Wollert K, Kempf T, Wallentin L . Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017; 63(1):140-151. DOI: 10.1373/clinchem.2016.255174. View

2.
Modi A, Dwivedi S, Roy D, Khokhar M, Purohit P, Vishnoi J . Growth differentiation factor 15 and its role in carcinogenesis: an update. Growth Factors. 2019; 37(3-4):190-207. DOI: 10.1080/08977194.2019.1685988. View

3.
Arend S, Mallat M, Westendorp R, van der Woude F, van Es L . Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 1997; 12(8):1672-9. DOI: 10.1093/ndt/12.8.1672. View

4.
Nair V, Robinson-Cohen C, Smith M, Bellovich K, Bhat Z, Bobadilla M . Growth Differentiation Factor-15 and Risk of CKD Progression. J Am Soc Nephrol. 2017; 28(7):2233-2240. PMC: 5491285. DOI: 10.1681/ASN.2016080919. View

5.
Lindahl B . The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem. 2013; 59(11):1550-2. DOI: 10.1373/clinchem.2013.212811. View